ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1922

Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom

Raj Sengupta1, Shruti Narasimham2, Borja Mato3, Matic Meglic3, Chiara Perella3, Paula Pamies4 and Paul Emery5, 1The Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Novartis Ireland Ltd, Dublin, Ireland, Dublin, Ireland, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals UK Ltd, London, UK, London, United Kingdom, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Ankylosing spondylitis (AS), Diagnostic criteria, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes II (1919–1922)

Session Type: Abstract Session

Session Time: 2:45PM-3:00PM

Background/Purpose: On an average, there is a delay of 6.7 years between symptom onset and diagnosis of axial spondyloarthritis (axSpA)1. Since traditional approaches to improving early axSpA identification have had limited success, predictive automated analyses on patient records may help alleviate the burden on healthcare providers2-5. Here, we report the results from a machine learning (ML) algorithm developed with UK electronic health records (EHRs) Clinical Practice Research Datalink (CPRD) data, to estimate the probability or likelihood of a pt being diagnosed with axSpA based on prior clinical indicators and pt history.

Methods: Primary care UK EHR data – CPRD GOLD was used to identify pts with axSpA and healthy controls (HC) (Figure). Pts aged ≥18 years, with first diagnosis date of axSpA within the identification period (01-Jan-2005 to 31-Dec-2018) and fulfilling CPRD research acceptability criteria were included in the study. Data pertaining to clinical presentation, consultation, referral, test, and therapy history were extracted for individual pt prior to diagnosis of axSpA. A total of 5090 pts with axSpA satisfied the acceptability criteria. HC were randomly sampled to create a subset of one unique HC matched to each pt with axSpA, resulting in 5089 HC. ML usable features derived from the total population (pts with axSpA and HC) numbered 820. After using a further exclusion criterion for the pts with axSpA and HC who had ≥1 out of 820 usable features, the final dataset included 7813 pts (3902 pts with axSpA and 3911 HC). This combined dataset was randomly split (67:33) into a train (N=5237) and a test (N=2576) dataset. A Random Forest (RF) model was trained on the train dataset. Cross-validation was performed for hyper-parameter tuning of the RF classifier. Once the model was trained, accuracy, precision, and F-1 scores were obtained with the test dataset.

Results: The RF based algorithm resulted in a high level of accuracy (88.12%), with precision of 0.95 for pts with axSpA and 0.83 for HC (Figure). RF algorithm identified 89 best clinical predictors (out of 820 used as inputs) that differentiated between pt and HC such as: total number of tests, total number of referrals, first age of consultation, first symptom age, number of low back pain symptoms. The sensitivity of the model was 75.04% and positive predictive value was 80.88%. The specificity of the model was 0.96 and negative predictive value was 82.56%.

Conclusion: The ML algorithm demonstrated a high level of accuracy and precision in the identification of possible cases of axSpA, which may be useful in reducing the delay in diagnosis. Previous studies have successfully demonstrated automated cohort identification of axSpA in large datasets, with only a few using ML based approaches for diagnosis from patient medical history. While the model supports previous work in axSpA2-5, it needs further validation in routine clinical practice and this exploration is ongoing.

References:

  1. Zhao SS, et al. Rheumatology 2021;60:1620–28.
  2. Walsh JA, et al. Current opinion in rheumatology 2019;31:362.
  3. Walsh JA, et al. BMC musculoskeletal disorders 2018;19:1–7.
  4. Walsh JA, et al. Arthritis care & research 2017;69:1414–20.
  5. Walsh JA, et al. The Journal of rheumatology 2020;47:42–49.

Figure: Automated axSpA diagnosis/rheumatology referral via pattern recognition in electronic patient data using ML


Disclosures: R. Sengupta, Merck Sharp & Dohme, 1, 5, 6, AbbVie, 1, 5, 6, Biogen, 1, 5, 6, Celgene, 1, 5, 6, Novartis, 1, 5, 6, Pfizer, 1, 5, 6, Roche, 1, 5, 6, UCB, 1, 5, 6; S. Narasimham, Novartis, 3, 11; B. Mato, Novartis, 3, 11; M. Meglic, Novartis, 3; C. Perella, Novartis, 3; P. Pamies, Novartis, 3; P. Emery, Abbvie, 2, 5, 6, Sanofi, 2, 6, BMS, 2, 5, 6, Novartis, 2, 6, Gilead, 2, 6, Samsung, 2, 5, 6, Celltrion, 2, 6, Eli Lilly, 2, 5, 6, MSD, 2, 6, Pfizer, 2, 6, Roche, 2, 6, Amgen Inc., 2, 6, Sandoz, 2, UCB, 1, 5, 6, Boehringer Ingelheim, 1, 5, 6, Merck, 1, 5, 6.

To cite this abstract in AMA style:

Sengupta R, Narasimham S, Mato B, Meglic M, Perella C, Pamies P, Emery P. Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/early-and-accurate-diagnosis-of-patient-with-axial-spondyloarthritis-using-machine-learning-a-predictive-analysis-from-electronic-health-records-in-united-kingdom/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-and-accurate-diagnosis-of-patient-with-axial-spondyloarthritis-using-machine-learning-a-predictive-analysis-from-electronic-health-records-in-united-kingdom/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology